Document detail
ID

oai:arXiv.org:2408.11785

Topic
Computer Science - Computer Vision... Computer Science - Artificial Inte...
Author
Zhou, Haipeng Wang, Honqiu Ye, Tian Xing, Zhaohu Ma, Jun Li, Ping Wang, Qiong Zhu, Lei
Category

Computer Science

Year

2024

listing date

8/28/2024

Keywords
computer temporal boundary shadow
Metrics

Abstract

Video Shadow Detection (VSD) aims to detect the shadow masks with frame sequence.

Existing works suffer from inefficient temporal learning.

Moreover, few works address the VSD problem by considering the characteristic (i.e., boundary) of shadow.

Motivated by this, we propose a Timeline and Boundary Guided Diffusion (TBGDiff) network for VSD where we take account of the past-future temporal guidance and boundary information jointly.

In detail, we design a Dual Scale Aggregation (DSA) module for better temporal understanding by rethinking the affinity of the long-term and short-term frames for the clipped video.

Next, we introduce Shadow Boundary Aware Attention (SBAA) to utilize the edge contexts for capturing the characteristics of shadows.

Moreover, we are the first to introduce the Diffusion model for VSD in which we explore a Space-Time Encoded Embedding (STEE) to inject the temporal guidance for Diffusion to conduct shadow detection.

Benefiting from these designs, our model can not only capture the temporal information but also the shadow property.

Extensive experiments show that the performance of our approach overtakes the state-of-the-art methods, verifying the effectiveness of our components.

We release the codes, weights, and results at \url{https://github.com/haipengzhou856/TBGDiff}.

;Comment: ACM MM2024

Zhou, Haipeng,Wang, Honqiu,Ye, Tian,Xing, Zhaohu,Ma, Jun,Li, Ping,Wang, Qiong,Zhu, Lei, 2024, Timeline and Boundary Guided Diffusion Network for Video Shadow Detection

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw